What Is a Left Atrial Thrombus? Causes and Treatment

A left atrial thrombus is a blood clot that forms inside the left atrium, one of the heart’s upper chambers. It develops when blood pools and stagnates rather than flowing smoothly forward, and the overwhelming majority of these clots lodge in a small, finger-shaped pouch called the left atrial appendage. The reason this matters is stroke: a piece of the clot can break free, travel through the bloodstream, and block an artery supplying the brain or another organ. Understanding what causes these clots and how they are managed involves everything from the anatomy of a small cardiac pouch to newer blood thinners and implantable devices.

Where the Clot Forms and Why

The left atrial appendage is a remnant of the embryonic left atrium, and its shape makes it especially prone to trapping stagnant blood. In patients with the most common trigger for left atrial clots, atrial fibrillation, roughly 90% of thrombi are found in this appendage rather than elsewhere in the chamber.¹ The appendage comes in several shapes across the population, and some morphologies create deeper recesses where blood flow drops to almost nothing during irregular heart rhythms.

Clot formation in the left atrium follows the same three-part process that drives clots elsewhere in the body: damage or dysfunction of the inner lining of the heart, stagnant blood flow, and changes in the blood’s tendency to clot. When the heart is fibrillating, the atrium quivers rather than contracting forcefully, so blood barely moves through the appendage. That stagnation, combined with changes to the endocardial surface and shifts in clotting-factor activity, creates the conditions for a thrombus to grow.¹

Atrial Fibrillation as the Primary Cause

Atrial fibrillation is by far the most common condition behind left atrial thrombus formation. A meta-analysis pooling more than 20,000 patients with nonvalvular atrial fibrillation who underwent imaging found that about 10% had a left atrial thrombus at the time they were scanned.² That number is higher than many people expect, because most of these clots produce no symptoms until they cause damage. The same analysis found that having a left atrial thrombus was associated with roughly a 3.5-fold increase in the risk of stroke or systemic embolism compared to patients without one.²

Not every patient with atrial fibrillation carries the same risk. Doctors use scoring systems to estimate how likely a person is to throw a clot, factoring in age, prior stroke, high blood pressure, diabetes, heart failure, and vascular disease. But newer research suggests those scores can be refined. Measurements of how well the left atrium stretches and contracts, captured during echocardiography, add predictive value on top of the standard score. In one study, patients who had experienced an embolic event had markedly reduced atrial wall movement, and a specific strain cutoff independently predicted embolism even after accounting for the conventional risk factors.³ Similar findings apply to measurements focused on the appendage itself, where uneven contraction patterns have been linked to higher embolism rates.⁴

Valvular Heart Disease and Other Contributors

Atrial fibrillation is not the only culprit. Mitral stenosis, a narrowing of the valve between the left atrium and left ventricle, has a long-established link to left atrial thrombus. When the mitral valve cannot open fully, blood backs up in the atrium, the chamber dilates, and flow slows. Left atrial thrombus formation is a well-known complication of severe mitral stenosis and a recognized source of systemic embolism.⁵ Other forms of rheumatic heart disease contribute in a similar way.

Heart failure, whether from weakened pumping or stiff chambers, also enlarges the left atrium and reduces flow velocities. And conditions that make the blood itself more prone to clotting, such as certain inherited or acquired clotting disorders, can push a person over the threshold even when the heart rhythm is normal. In practice, many patients have overlapping risk factors: atrial fibrillation and heart failure and valve disease together, each amplifying the others.

How a Left Atrial Thrombus Is Detected

Standard transthoracic echocardiography, the ultrasound probe placed on the chest wall, can pick up large clots sitting in the main body of the left atrium. But it frequently misses the smaller or more common clots tucked inside the appendage. In a study of patients with rheumatic heart disease who went on to surgery, transthoracic imaging detected thrombi in only about 69% of confirmed cases, while transesophageal echocardiography, where a probe is guided into the esophagus to sit directly behind the heart, caught all of them.⁶ Transesophageal echocardiography remains the standard before procedures like cardioversion or catheter ablation, where dislodging an undetected clot could trigger a stroke.

Cardiac CT has become a strong alternative when transesophageal imaging is impractical or refused. A meta-analysis found that when a delayed-imaging technique was used, CT achieved near-perfect sensitivity and specificity for detecting appendage thrombi, with accuracy around 99%.⁷ The delayed-scan approach works because contrast dye that has not yet washed out of the appendage fills around any clot, making it stand out. Without that delayed phase, CT tends to overcall slow-flowing blood as thrombus, producing false positives.

Cardiac MRI is also an option, though its track record is more mixed. One meta-analysis reported that a specific delayed-enhancement MRI technique reached perfect sensitivity with around 99% specificity.⁸ However, an earlier pilot study of contrast-enhanced MRI found much less encouraging numbers, with sensitivities in the range of 35 to 47%.⁹ The discrepancy comes down to technique: which MRI sequence is used, how imaging is timed, and how experienced the reading team is. In practice, MRI is more often a secondary option reserved for patients who cannot receive iodinated contrast for CT or who need additional cardiac assessment for other reasons.

Lookalikes That Can Fool Imaging

Not every mass in the left atrium is a clot. One common mimic is a structure called the coumadin ridge (also known as the left atrial ridge), a fold of tissue sitting between the appendage opening and the left upper pulmonary vein. It is a normal anatomical variant, but when it is prominent, it can look strikingly like a thrombus or even a tumor on imaging.¹⁰ Its name is a dark joke: patients have been unnecessarily started on warfarin (brand name Coumadin) because the ridge was misidentified as a clot. In rare cases, a true mass such as a fibroelastoma can arise from the ridge itself, adding another layer of diagnostic confusion.¹¹

Another phenomenon worth knowing about is spontaneous echo contrast, sometimes called “smoke” because of how it looks on ultrasound. This swirling haze represents sluggish blood flow without a formed clot and is considered a precursor to thrombus formation.¹² Finding smoke in the left atrium does not mean a clot is present, but it raises the alarm that conditions are ripe for one to develop. Clinicians often escalate anticoagulation decisions based on the presence of dense spontaneous contrast even if no frank thrombus is seen.

Stroke Risk and Other Embolic Events

A left atrial thrombus is not a passive bystander. Pieces can break off and travel to the brain, spleen, kidneys, or limb arteries. In one long-term follow-up study of patients with documented left atrial thrombus, the stroke or embolic event rate ran at about 10% per year, and annual mortality was roughly 16%.¹³ These are sobering numbers and help explain why the medical response to finding a clot in the left atrium is aggressive.

Even patients who are already on blood thinners are not fully protected. Case reports document embolic strokes occurring in patients taking newer anticoagulants for known appendage thrombi.¹⁴ The clot may be too organized or too large for the anticoagulant to dissolve quickly, or a fragment may dislodge before the drug has had time to work. This underscores the point that treatment aims both to dissolve or stabilize existing clots and to prevent new ones.

Anticoagulation Treatment

Blood thinners are the first-line treatment. For decades, warfarin was the only oral option. It works, but it requires regular blood monitoring and is sensitive to diet, other medications, and individual variation. In the past several years, direct oral anticoagulants (often called DOACs) have taken over much of the landscape.

A recent comparison study found that over about a year of follow-up, left atrial thrombus resolved in roughly 62% of patients overall. The resolution rate was significantly higher in those taking DOACs than in those on warfarin, and standard-dose DOACs in particular outperformed warfarin even when warfarin was well-managed. Patients on DOACs also had fewer major bleeding events.¹⁵ These results align with a broader trend in cardiology favoring DOACs for their convenience, more predictable dosing, and at least comparable safety profile.

That said, not every clot dissolves. Some become organized, meaning they develop an internal structure of fibrous tissue that makes them resistant to anticoagulation. When repeat imaging shows the thrombus persisting despite adequate treatment, the approach needs to be reconsidered.

Preprocedural Screening Before Cardioversion and Ablation

If you have atrial fibrillation and your doctor wants to restore a normal heart rhythm through electrical cardioversion or catheter ablation, the first step is usually confirming that no clot is sitting in the appendage. Shocking or ablating the heart while a thrombus is present risks dislodging it. Guidelines call for at least three weeks of anticoagulation before the procedure, and many centers still perform transesophageal echocardiography just before going ahead.

Even with continuous anticoagulant use, a small percentage of patients are found to have appendage thrombi at the time of preprocedural imaging. A multicenter review of over 1,200 patients on newer anticoagulants found thrombi in about 4% before planned cardioversion or ablation.¹⁶ When a clot is discovered, the procedure is postponed, anticoagulation is intensified or switched, and imaging is repeated weeks later. This is inconvenient but far safer than proceeding.

Managing Persistent or Resistant Clots

When a left atrial thrombus does not resolve after an appropriate course of anticoagulation, clinicians face a difficult decision. Expert guidance recommends individualizing the approach. Options include switching to a different class of anticoagulant: if the patient was on a factor Xa inhibitor (such as apixaban or rivaroxaban), trying a direct thrombin inhibitor (dabigatran), or switching to warfarin with a tailored target range. The reverse switch is also used.¹⁷

In certain clinical scenarios, nonpharmacological alternatives come into play. Left atrial appendage closure devices, small implants delivered through a catheter that seal off the appendage, can eliminate the main site of clot formation. These were developed primarily for patients who cannot tolerate long-term blood thinners, but they are also considered when thrombus keeps recurring. The devices are effective at preventing new clots in the appendage, though they carry their own complication: a small risk of clot forming on the device surface itself. A systematic review of device-related thrombus found that when treated with blood thinners (typically low-molecular-weight heparin or oral anticoagulants), complete resolution occurred in about 95% of cases, usually within a few weeks.¹⁸

Some patients develop recurrent clots on these devices despite treatment, particularly those with poor adherence to anticoagulants or unstable INR control on warfarin.¹⁹ In these refractory cases, the clinical team weighs whether to intensify medical therapy, add antiplatelet agents, or in rare situations, consider surgical removal.

Surgical Removal

Open surgery for a left atrial thrombus is uncommon today as a standalone procedure. It is most often performed when a patient already needs cardiac surgery for another reason, typically valve repair or replacement. During mitral valve surgery, for example, the surgeon can directly remove the clot, reduce the size of a massively dilated left atrium, and address the underlying valve problem all at once.²⁰ Giant organized thrombi, the kind that have hardened and sometimes fill a significant portion of the atrium, are the most likely to require surgical extraction because they are too large and fibrous to dissolve with medications alone.

Blood Markers That May Signal Hidden Clots

Researchers have been looking for blood tests that might flag patients who harbor a left atrial thrombus before they undergo imaging. One study of anticoagulated patients with atrial fibrillation found that elevated levels of NT-proBNP (a marker of heart wall stress) and elevated red cell distribution width (a measure of variation in red blood cell size) were each independently associated with the presence of a left atrial or appendage thrombus. Surprisingly, D-dimer, a commonly used marker for clotting activity, was not independently correlated in the same analysis.²¹

These biomarkers are not accurate enough to replace imaging, but they could help triage patients. If a blood draw shows normal levels of both markers, the chance of finding a thrombus on transesophageal echocardiography may be low enough to reconsider whether the invasive imaging is necessary in that specific case. The research here is still evolving, and no guidelines currently endorse skipping imaging based on biomarkers alone.

Artificial Intelligence in Thrombus Detection

One of the frontiers in this field involves training artificial intelligence to detect appendage thrombi from standard transthoracic echocardiograms combined with clinical data. The appeal is obvious: if an algorithm could reliably flag high-risk patients using the same noninvasive ultrasound that is already widely performed, it could reduce the number of patients who need to swallow a transesophageal probe. Early registry data from a large European effort (the LATTEE registry) has been used to build and test such models.²² The technology is promising but remains investigational, and the clinical workflow still depends on transesophageal imaging or CT for definitive answers. What AI may eventually change is who gets sent for that definitive test and how urgently.

Why Medication Adherence Matters More Than People Think

A recurring theme across the clinical literature is that gaps in anticoagulation, even short ones, create windows for thrombus formation or growth. Patients who skip doses of their blood thinner, who stop taking it for a dental procedure and forget to restart, or who have wildly fluctuating INR levels on warfarin are at disproportionate risk. This is not just theoretical. Case reports of device-related thrombus recurrence have been linked directly to suboptimal adherence and irregular monitoring.¹⁹ One of the advantages DOACs hold over warfarin in real-world use is that their more predictable pharmacology makes consistent anticoagulation easier to maintain even when monitoring is less frequent.

If you are on anticoagulation for atrial fibrillation or another condition associated with left atrial thrombus, the single most effective thing you can do is take the medication consistently. A perfectly chosen drug at the ideal dose does nothing if it is sitting in the bottle.